Usefulness of glycated albumin for early detection of deterioration of glycemic control state after discharge from educational admission

Murai, Jun; Soga, Sumiko; Saitō, Hiroshi; Koga, Masafumi

doi:10.1507/endocrj.ej12-0281

Cited by 10 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GA seems useful for early monitoring of the worsening of glycemic control in patients after discharge from hospital education programs. Because it rises faster than HbA1c, GA means that countermeasures can be taken promptly [73].…”

Section: Intermediate-term Glycemic Statusmentioning

confidence: 99%

Glycated albumin: from biochemistry and laboratory medicine to clinical practice

Dozio

Gaetano²,

Findeisen

et al. 2016

Endocrine

View full text Add to dashboard Cite

This review summarizes current knowledge about glycated albumin. We review the changes induced by glycation on the properties of albumin, the pathological implications of high glycated albumin levels, glycated albumin quantification methods, and the use of glycated albumin as a complementary biomarker for diabetes mellitus diagnosis and monitoring and for dealing with long-term complications. The advantages and limits of this biomarker in different clinical settings are also discussed.

show abstract

Section: Intermediate-term Glycemic Statusmentioning

confidence: 99%

Glycated albumin: from biochemistry and laboratory medicine to clinical practice

Dozio

Gaetano²,

Findeisen

et al. 2016

Endocrine

View full text Add to dashboard Cite

show abstract

“…It is possible to achieve good glycemic control in a short time by measuring GA because therapeutic efficacy in the early stages may be evaluated. We also demonstrated that GA measurements were useful for predicting deteriorations in glycemic control [11]. Furthermore, while HbA1c levels primarily reflect mean plasma glucose, GA levels have been shown to reflect postprandial plasma glucose/glycemic excursions in addition to mean plasma glucose [7,[12][13][14].…”

Section: Introductionmentioning

confidence: 78%

“…We also demonstrated the usefulness of GA for predicting poor glycemic control after patients had been discharged from diabetes education hospitalization [11]. The rebound of HbA1c could not be evaluated at the time of the GA rebound.…”

Section: Discussionmentioning

confidence: 97%

Usefulness of glycated albumin in decisions regarding the discontinuation of a diabetes drug and factors associated with poor glycemic control following discontinuation in patients with type 2 diabetes mellitus

Masumoto¹,

Otsuki²,

Iwakawa

et al. 2016

Diabetol Int

Self Cite

View full text Add to dashboard Cite

We studied the usefulness of glycated albumin (GA) for decisions regarding the discontinuation of a diabetes drug in type 2 diabetic patients with good glycemic control, and the factors associated with increases in GA following discontinuation of a diabetes drug in patients with type 2 diabetes mellitus. Sixteen patients (12 males and 4 females) were enrolled in the present study and discontinued one diabetes drug. When the change in GA was less than 1 % at 4 weeks after the discontinuation of the diabetes drug (DGA4w), discontinuation was continued (the continuous group, n = 10), but when the change in GA was more than a 1 %, the discontinued diabetes drug was resumed (the resume group, n = 6). In the continuous group, HbA1c at 12 weeks after discontinuation (6.2 ± 0.6 %) remained unchanged from its value at discontinuation (6.2 ± 0.7 %) , but it was significantly elevated at 12 weeks after discontinuation in the resume group (changing from 6.3 ± 0.1 to 7.0 ± 0.6 %). Age, duration of diabetes, and GA were significantly lower while body mass index (BMI) was significantly higher in the continuous group than in the resume group, but no significant difference in HbA1c was observed between the groups. The discontinuation of a diabetes drug in patients with low insulin secretion must be performed carefully because factors such as duration of diabetes, BMI, and GA showed significant differences between the continuous group and resume group in our study, and these indicators are known to be linked with insulin secretion.

show abstract

“…Its value is expressed in terms of percentage with respect to the total hemoglobin concentration and can be used as a diagnostic biomarker [ 1 ] and as a monitoring tool to assess treatment effectiveness in diabetic patients [ 41 ]. Despite being supported by large-scale clinical trials, i.e., the DCCT and the UKPDS, its employment suffers from some intrinsic disadvantages related to the breadth of the temporal window, which does not allow for accurately tracking rapid changes in glycemic control [ 52 , 53 , 54 ], and to its reliability under certain clinical circumstances such as hematologic disorders (variant hemoglobin, different types of anemia), recent blood transfusions, use of erythropoietin-based drugs, and pregnancy, which alter the lifespan of red blood cells hence affecting HbA1c measurements [ 16 , 41 , 55 ]. Moreover, there is evidence for inter-individual heterogeneity of glucose gradient across the membrane of red blood cells, which changes the dynamics of hemoglobin glycation hence impacting HbA1c assessment tests [ 56 ].…”

Section: Glycemic Control Biomarkersmentioning

confidence: 99%

Analytical Challenges in Diabetes Management: Towards Glycated Albumin Point-of-Care Detection

et al. 2022

View full text Add to dashboard Cite

Diabetes mellitus is a worldwide-spread chronic metabolic disease that occurs when the pancreas fails to produce enough insulin levels or when the body fails to effectively use the secreted pancreatic insulin, eventually resulting in hyperglycemia. Systematic glycemic control is the only procedure at our disposal to prevent diabetes long-term complications such as cardiovascular disorders, kidney diseases, nephropathy, neuropathy, and retinopathy. Glycated albumin (GA) has recently gained more and more attention as a control biomarker thanks to its shorter lifespan and wider reliability compared to glycated hemoglobin (HbA1c), currently the “gold standard” for diabetes screening and monitoring in clinics. Various techniques such as ion exchange, liquid or affinity-based chromatography and immunoassay can be employed to accurately measure GA levels in serum samples; nevertheless, due to the cost of the lab equipment and complexity of the procedures, these methods are not commonly available at clinical sites and are not suitable to home monitoring. The present review describes the most up-to-date advances in the field of glycemic control biomarkers, exploring in particular the GA with a special focus on the recent experimental analysis techniques, using enzymatic and affinity methods. Finally, analysis steps and fundamental reading technologies are integrated into a processing pipeline, paving the way for future point-of-care testing (POCT). In this view, we highlight how this setup might be employed outside a laboratory environment to reduce the time from measurement to clinical decision, and to provide diabetic patients with a brand-new set of tools for glycemic self-monitoring.

show abstract

Usefulness of glycated albumin for early detection of deterioration of glycemic control state after discharge from educational admission

Cited by 10 publications

References 18 publications

Glycated albumin: from biochemistry and laboratory medicine to clinical practice

Glycated albumin: from biochemistry and laboratory medicine to clinical practice

Usefulness of glycated albumin in decisions regarding the discontinuation of a diabetes drug and factors associated with poor glycemic control following discontinuation in patients with type 2 diabetes mellitus

Analytical Challenges in Diabetes Management: Towards Glycated Albumin Point-of-Care Detection

Contact Info

Product

Resources

About